Prestige Consumer Healthcare earnings release, August 6, 2026

Prestige Consumer Healthcare Inc. (PBH) · Form 8-K, Item 2.02 · Filed · SEC filing

Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results

• Q1 Revenue of $265.7 million up 6.5% versus prior year

• Q1 Organic sales growth of 3.2%, exceeding expectations

• Q1 Diluted EPS of $0.61; Adjusted Diluted EPS of $0.98, up versus prior year $0.95

• Q1 Cash from Operating Activities $70.8 million; Q1 Adjusted Non-GAAP Free Cash Flow of $83.7 million

• Closed the Breathe Right® and LaCorium acquisitions in June and July, respectively

• Raising fiscal 2027 outlook to include acquisitions; anticipate revenue of $1,290 to $1,315 million and Adjusted Diluted EPS outlook to $4.55 to $4.65

TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-August 6, 2026-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2027 ended June 30, 2026.

“First quarter performance exceeded our sales and earnings expectations, helped by strength across multiple categories that more than offset a challenging consumer backdrop and Clear Eyes® variability. We were also pleased to close the Breathe Right® acquisition late in the quarter, which added an incremental $6 million in revenue and is positioned well for long-term growth. These strong business results generated robust record adjusted free cash flow in the first quarter, leaving us well positioned to rapidly deleverage in the quarters ahead,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.

First Fiscal Quarter Ended June 30, 2026

Reported revenues in the first quarter of fiscal 2027 of $265.7 million increased 6.5% from $249.5 million in the first quarter of fiscal 2026 and increased 3.2% excluding the impacts of foreign currency and a $5.9 million contribution from the acquisition of Breathe Right® and its associated portfolio of brands. The revenue performance versus the prior year comparable period reflected strong organic growth in the

Gastrointestinal and

Dermatological categories as well as an increase in revenues associated with the acquisition of the Breathe Right® brand and its associated portfolio.

Reported net income for the first quarter of fiscal 2027 totaled $29.2 million, or $0.61 in earnings per diluted share, compared to $47.5 million, or $0.95 in diluted earnings per share, for the comparable period. On an adjusted non-GAAP basis first quarter fiscal 2027 net income totaled $46.5 million, or $0.98 in diluted earnings per share.

Adjustments to net income in the first quarter of fiscal 2027 included certain costs associated with acquisitions including integration, transition, purchase accounting, legal and various other costs, such as costs associated with improving and optimizing the acquired Pillar5 facility for increases in long-term capacity, and associated tax adjustments.

Free Cash Flow and Balance Sheet

The Company's net cash provided by operating activities for the first quarter of fiscal 2027 was $70.8 million, compared to $79.0 million during the prior year comparable period. Non-GAAP adjusted free cash flow in the first quarter of fiscal 2027 of $83.7 million increased compared to $78.2 million in the prior year first quarter. The material increase in free cash flow was attributable to the timing of working capital.

The Company's net debt position as of June 30, 2026 was approximately $2 billion. Subsequent to the quarter, on July 15, 2026 the Company issued $400 million of new 6.25% senior notes due 2034 which replaced the same principal of senior notes previously due in fiscal 2028. The new notes extend the maturity of the amount to July 15, 2034 moving the Company’s closest debt maturity to 2031.

Segment Review

In the fiscal first quarter 2027, the Company established a new product category, Wellness, Sleep & Other, and renamed certain existing product categories to help best incorporate the brands acquired in the Breathe Right® transaction.

North American OTC Healthcare

: Segment revenues of $226.2 million for the first quarter fiscal 2027 increased 6.4% compared to the prior year comparable quarter's segment revenues of $212.6 million. The revenue increase was broad-based and included strong organic sales growth in the Gastrointestinal, Dermatological, and Cough, Cold & Allergy categories, as well as an increase in the newly created Wellness, Sleep & Other category from the acquisition of the Breathe Right® brand.

International OTC Healthcare

: Fiscal first quarter 2027 segment revenues of $39.5 million increased 6.9% compared to $37.0 million reported in the prior year comparable period. The revenue performance was primarily driven by a $1.4 million contribution from the acquisition of the Breathe Right® brand.

Updated Fiscal 2027 Outlook

Ron Lombardi, Chief Executive Officer, stated, “Our strong initial first quarter performance gives us momentum in both revenue and earnings for full-year fiscal 2027. Our consumption remains healthy for our leading, trusted brands, and we continue to emphasize our proven marketing tactics to succeed in a challenging consumer environment. In addition, our portfolio diversity and business attributes leave us well positioned to manage the continued volatile supply for Clear Eyes®.”

“We are very excited about our recently closed Breathe Right portfolio and LaCorium Health acquisitions in mid-June and July, respectively, and both bring strong long-term growth prospects. Breathe Right® is a category-defining, global brand in the attractive better-breathing space, where we expect to grow the category domestically while expanding the brand's international presence. LaCorium's Dermal Therapy® brand is a leader in therapeutic skin care in Australia, and we anticipate strong sales growth under the Prestige Consumer Healthcare business model, driven by category growth, innovation, and continued geographic expansion."... (truncated)% to our revenue base and we expect the acquisitions to become increasingly accretive to profitability and cash flow as we move past the near-term and begin to realize business synergies and our brand growth objectives,” Mr. Lombardi concluded.

First Quarter Fiscal 2027 Conference Call, Accompanying Slide Presentation and Replay

The Company will host a conference call to review its first quarter fiscal 2027 results today, August 6, 2026 at 8:30 a.m. ET. The Company provides a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at http://www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. The slide presentation can be accessed from the Investor Relations page of the Company’s website by clicking on Webcasts and Presentations.

A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.

Non-GAAP and Other Financial Information

In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited) (In thousands, except per share data)

Three Months Ended June 30, – 20262025
Total Revenues265,710249,530
Cost of SalesCost of sales excluding depreciation126,466106,715
Cost of SalesCost of sales depreciation3,0562,484
Cost of SalesCost of sales129,522109,199
Cost of SalesGross profit136,188140,331
Operating ExpensesAdvertising and marketing34,66834,937
Operating ExpensesGeneral and administrative43,30328,456
Operating ExpensesDepreciation and amortization5,6975,182
Operating ExpensesTotal operating expenses83,66868,575
Operating ExpensesOperating income52,52071,756
Other expenseInterest expense, net13,94510,203
Other expenseOther expense (income), net34-224
Other expenseTotal other expense, net13,9799,979
Other expenseIncome before income taxes38,54161,777
Other expenseProvision for income taxes9,36414,311
Other expenseNet income29,17747,466
Earnings per share:Basic0.610.96
Earnings per share:Diluted0.610.95
Weighted average shares outstanding:Basic47,46249,475
Weighted average shares outstanding:Diluted47,60449,833
Comprehensive income, net of tax:Currency translation adjustments-1,3105,404
Comprehensive income, net of tax:Total other comprehensive (loss) income-1,3105,404
Comprehensive income, net of tax:Comprehensive income27,86752,870

Income Statement

Three Months Ended June 30, 2026 — (Unaudited) (in thousands)

Three Months Ended June 30, 2026 – North American OTC HealthcareThree Months Ended June 30, 2026 – International OTC HealthcareConsolidated
Total segment revenues*226,20639,504265,710
Cost of sales110,26519,257129,522
Gross profit115,94120,247136,188
Advertising and marketing28,9305,73834,668
Contribution margin87,01114,509101,520
Other operating expenses49,000
Operating income52,520

Income Statement

Three Months Ended June 30, 2025 — *Intersegment revenues of $0.7 million were eliminated from the North American OTC Healthcare segment. (in thousands)

Three Months Ended June 30, 2025 – North American OTC HealthcareThree Months Ended June 30, 2025 – International OTC HealthcareConsolidated
Total segment revenues*212,57836,952249,530
Cost of sales92,17817,021109,199
Gross profit120,40019,931140,331
Advertising and marketing28,9545,98334,937
Contribution margin91,44613,948105,394
Other operating expenses33,638
Operating income71,756

Income Statement

Three Months Ended June 30, — Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related Non-GAAP Organic Revenue Change percentage: (in thousands)

Three Months Ended June 30, – 20262025
GAAP Total Revenues265,710249,530
Revenue Change6.5
Adjustments:Revenues associated with acquisition (a)-5,945
Adjustments:Impact of foreign currency exchange rates2,086
Adjustments:Total adjustments-5,9452,086
Adjustments:Non-GAAP Organic Revenues259,765251,616
Adjustments:Non-GAAP Organic Revenue Change3.2

Income Statement

Three Months Ended June 30, — Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and related Non-GAAP Adjusted Gross Margin percentage: (in thousands)

Three Months Ended June 30, – 20262025
GAAP Total Revenues265,710249,530
GAAP Gross Profit136,188140,331
GAAP Gross Profit as a Percentage of GAAP Total Revenue51.3%56.2
Adjustments:Amortization of inventory fair value step‑up2,840
Adjustments:Acquired facility remediation, period overhead and idle capacity costs (a)7,148
Adjustments:Total adjustments9,988
Adjustments:Non-GAAP Adjusted Gross Margin146,176140,331
Adjustments:Non-GAAP Adjusted Gross Margin as a Percentage of GAAP Total Revenues55.0%56.2

Income Statement

Three Months Ended June 30, (in thousands)

Three Months Ended June 30, – 20262025
GAAP General and Administrative Expense43,30328,456
GAAP General and Administrative Expense as a Percentage of GAAP Total Revenue16.311.4
Adjustments:Costs associated with acquisition (a)12,823
Adjustments:Total adjustments12,823
Adjustments:Non-GAAP Adjusted General and Administrative Expense30,48028,456
Adjustments:Non-GAAP Adjusted General and Administrative Expense Percentage as a Percentage of GAAP Total Revenues11.511.4

Income Statement

Three Months Ended June 30, — Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin: (in thousands)

Three Months Ended June 30, – 20262025
GAAP Net Income29,17747,466
Interest expense, net13,94510,203
Provision for income taxes9,36414,311
Depreciation and amortization8,7537,666
Non-GAAP EBITDA61,23979,646
Non-GAAP EBITDA Margin23.0%31.9
Adjustments:Amortization of inventory fair value step‑up2,840
Adjustments:Acquired facility remediation, period overhead and idle capacity costs (a)7,148
Adjustments:Costs associated with acquisitions in G&A (b)12,823
Adjustments:Total adjustments22,811
Adjustments:Non-GAAP Adjusted EBITDA84,05079,646
Adjustments:Non-GAAP Adjusted EBITDA Margin31.6%31.9

Balance Sheet

June 30, 2026 — (Unaudited) (in thousands)

June 30, 2026March 31, 2026
Cash and cash equivalents89,12763,868
Accounts receivable, net of allowance of $19,916 and $18,187, respectively187,355191,920
Inventories190,215159,132
Prepaid expenses and other current assets30,11716,564
Total current assets496,814431,484
Property, plant and equipment, net117,178121,689
Operating lease right-of-use assets26,04027,780
Finance lease right-of-use assets, net20,95621,776
Goodwill650,795581,109
Intangible assets, net3,243,3582,299,605
Other long-term assets13,43210,870
Total Assets4,568,5733,494,313
Current liabilitiesCurrent portion of long-term debt10,450
Current liabilitiesAccounts payable36,84922,791
Current liabilitiesAccrued interest payable18,01515,578
Current liabilitiesOperating lease liabilities, current portion7,0106,910
Current liabilitiesFinance lease liabilities, current portion2,6992,656
Current liabilitiesOther accrued liabilities78,78372,989
Current liabilitiesTotal current liabilities153,806120,924
Current liabilitiesLong-term debt, net2,007,235993,953
Current liabilitiesDeferred income tax liabilities448,824447,417
Current liabilitiesLong-term operating lease liabilities, net of current portion19,12920,955
Current liabilitiesLong-term finance lease liabilities, net of current portion17,27617,968
Current liabilitiesOther long-term liabilities5,5875,580
Current liabilitiesTotal Liabilities2,651,8571,606,797
Current liabilitiesTotal Stockholders' Equity1,916,7161,887,516
Current liabilitiesTotal Liabilities and Stockholders' Equity4,568,5733,494,313

Balance Sheet

Three Months Ended June 30, — (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Net income29,17747,466
Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization8,7537,666
Adjustments to reconcile net income to net cash provided by operating activities:Loss on disposal of property and equipment191
Adjustments to reconcile net income to net cash provided by operating activities:Deferred and other income taxes1935,827
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of debt origination costs465442
Adjustments to reconcile net income to net cash provided by operating activities:Amortization of acquired inventory step-up2,840
Adjustments to reconcile net income to net cash provided by operating activities:Stock-based compensation costs3,9943,682
Adjustments to reconcile net income to net cash provided by operating activities:Non-cash operating lease cost2,0901,947
Changes in operating assets and liabilities, net of the effects of acquisitions:Accounts receivable3,45027,343
Changes in operating assets and liabilities, net of the effects of acquisitions:Inventories-2,828-4,441
Changes in operating assets and liabilities, net of the effects of acquisitions:Prepaid expenses and other current assets1,557-10,946
Changes in operating assets and liabilities, net of the effects of acquisitions:Accounts payable13,4032,756
Changes in operating assets and liabilities, net of the effects of acquisitions:Accrued liabilities9,831-813
Changes in operating assets and liabilities, net of the effects of acquisitions:Operating lease liabilities-2,095-1,916
Changes in operating assets and liabilities, net of the effects of acquisitions:Other-233
Changes in operating assets and liabilities, net of the effects of acquisitions:Net cash provided by operating activities70,78879,013
Investing ActivitiesPurchases of property, plant and equipment-3,703-838
Investing ActivitiesAcquisitions, net of cash acquired-1,045,000
Investing ActivitiesDeposits for business acquisitions and other-15,034-1,100
Investing ActivitiesNet cash (used in) investing activities-1,063,737-1,938
Financing ActivitiesProceeds from issuance of Term Loan1,045,000
Financing ActivitiesNet (decrease) increase in line of credit653
Financing ActivitiesPayments of debt costs-22,476
Financing ActivitiesPayments of finance leases-576-608
Financing ActivitiesProceeds from exercise of stock options3,155
Financing ActivitiesFair value of shares surrendered as payment of tax withholding-2,661-4,054
Financing ActivitiesRepurchase of common stock-34,775
Financing ActivitiesOther-1,4860
Financing ActivitiesNet cash provided by (used in) financing activities1,018,454-36,282
Financing ActivitiesEffects of exchange rate changes on cash and cash equivalents-246825
Financing ActivitiesIncrease in cash and cash equivalents25,25941,618
Financing ActivitiesCash and cash equivalents - beginning of period63,86897,884
Financing ActivitiesCash and cash equivalents - end of period89,127139,502
Financing ActivitiesInterest paid11,37911,501

Cash Flow

$1,100 to $1,121 million (in millions)

Revenue$1,100 to $1,121 million$1,290 to $1,315 million
Organic Revenue Growth+1.0% to +3.0%+1.0% to +3.0%
Adjusted Diluted E.P.S.$4.42 to $4.51$4.55 to $4.65
Adjusted Free Cash Flow$250 million or more$270 million or more

Cash Flow

Three Months Ended June 30, — Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow and Non-GAAP Adjusted Free Cash Flow: (in thousands)

Three Months Ended June 30, – 20262025
GAAP Net Income29,17747,466
Adjustments:Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows18,52619,564
Adjustments:Changes in operating assets and liabilities, net of effects of acquisitions as shown in the Statement of Cash Flows23,08511,983
Adjustments:Total adjustments41,61131,547
Adjustments:GAAP Net cash provided by operating activities70,78879,013
Adjustments:Purchases of property and equipment-3,703-838
Adjustments:Non-GAAP Free Cash Flow67,08578,175
Adjustments:Acquisition and other costs paid16,664
Adjustments:Non-GAAP Adjusted Free Cash Flow83,74978,175

Cash Flow

and Projected Non-GAAP Adjusted Free Cash Flow: (in millions)

Projected FY'27 GAAP Net cash provided by operating activities277
Additions to property and equipment for cash-26
Projected FY'27 Non-GAAP Free Cash Flow251
Acquisition and other costs paid19
Projected FY'27 Non-GAAP Adjusted Free Cash Flow270
Full release

Note Regarding Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "guidance," "outlook," "may," "will," "would," “believe,” “momentum,” "expect," “look forward,” "anticipate,” “increasingly,” “positioned,” or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the Company's future operating results including revenues, organic growth, diluted earnings per share, and adjusted free cash flow; consumption trends; the expected impact of Breathe Right® and LaCorium Health acquisitions on the Company’s revenue and cash flow; and the Company’s ability to manage through the current environment through its business strategy and diverse product portfolio. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of business and economic conditions, including as a result of evolving U.S. and international tariffs, labor shortages, inflation and geopolitical instability, consumer trends, the impact of the Company’s advertising and marketing and new product development initiatives, customer inventory management initiatives, fluctuating foreign exchange rates, competitive pressures, and the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption as a result of labor shortages. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic reports filed with the Securities and Exchange Commission.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips, Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, as well as Hydralyte® rehydration products and the Dermal Therapy® line of therapeutic skin care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Income and Comprehensive Income

(Unaudited)

Prestige Consumer Healthcare Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Income

Business Segments

(Unaudited)

*Intersegment revenues of $0.7 million were eliminated from the North American OTC Healthcare segment.

* Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.

About Non-GAAP Financial Measures... (truncated)Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense Percentage, Non-GAAP EBITDA, Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted Diluted EPS, Non-GAAP Free Cash Flow, Non-GAAP Adjusted Free Cash Flow, and Net Debt. We use these NGFMs internally, along with GAAP information, in evaluating our operating performance and in making financial and operational decisions. We believe that the presentation of these NGFMs provides investors with greater transparency, and provides a more complete understanding of our business than could be obtained absent these disclosures, because the supplemental data relating to our financial condition and results of operations provides additional ways to view our operation when considered with both our GAAP results and the reconciliations below. In addition, we believe that the presentation of each of these NGFMs is useful to investors for period-to-period comparisons of results in assessing shareholder value, and we use these NGFMs internally to evaluate the performance of our personnel and also to evaluate our operating performance and compare our performance to that of our competitors.

These NGFMs are not in accordance with GAAP, should not be considered as a measure of profitability or liquidity, and may not be directly comparable to similarly titled NGFMs reported by other companies. These NGFMs have limitations and they should not be considered in isolation from or as an alternative to their most closely related GAAP measures reconciled below. Investors should not rely on any single financial measure when evaluating our business. We recommend investors review the GAAP financial measures included in this earnings release. When viewed in conjunction with our GAAP results and the reconciliations below, we believe these NGFMs provide greater transparency and a more complete understanding of factors affecting our business than GAAP measures alone.

NGFMs Defined

We define our NGFMs presented herein as follows:

• Non-GAAP Organic Revenues

: GAAP Total Revenues excluding revenues associated with acquisition and the impact of foreign currency exchange rates in the periods presented.

• Non-GAAP Organic Revenue Change Percentage

: Calculated as the change in Non-GAAP Organic Revenues from prior year divided by prior year Non-GAAP Organic Revenues.

• Non-GAAP Adjusted Gross Margin

: GAAP Gross Profit minus amortization of inventory fair value step-up, acquired facility remediation, period overhead and idle capacity costs.

• Non-GAAP Adjusted Gross Margin Percentage

: Calculated as Non-GAAP Adjusted Gross Margin divided by GAAP Total Revenues.

• Non-GAAP Adjusted General and Administrative Expense

: GAAP General and Administrative expenses minus costs associated with acquisition.

• Non-GAAP Adjusted General and Administrative Expense Percentage

: Calculated as Non-GAAP Adjusted General and Administrative expense divided by GAAP Total Revenues.

• Non-GAAP EBITDA

: GAAP Net Income before interest expense, net, provision for income taxes, and depreciation and amortization.

• Non-GAAP EBITDA Margin

: Calculated as Non-GAAP EBITDA divided by GAAP Total Revenues.

• Non-GAAP Adjusted EBITDA:

Non-GAAP EBITDA before amortization of inventory fair value step‑up, acquired facility remediation, period overhead and idle capacity costs and costs associated with acquisitions.

• Non-GAAP Adjusted EBITDA Margin:

Calculated as Non-GAAP adjusted EBITDA divided by GAAP Total Revenues.

• Non-GAAP Adjusted Net Income

: GAAP Net Income before amortization of inventory fair value step-up, depreciation of idle assets during remediation period, acquired facility remediation, period overhead and idle capacity costs, costs associated with acquisitions in General and Administrative Expense, and applicable tax impact associated with these items.

• Non-GAAP Adjusted Diluted EPS

: Calculated as Non-GAAP Adjusted Net Income, divided by the diluted weighted average number of shares outstanding during the period.

• Non-GAAP Free Cash Flow

: Calculated as GAAP Net cash provided by operating activities less cash paid for capital expenditures.

• Non-GAAP Adjusted Free Cash Flow:

Non-GAAP free cash flow plus acquisition costs paid.

• Net Debt

: Calculated as total principal amount of debt outstanding ($2,045,000 at June 30, 2026) less cash and cash equivalents ($89,127 at June 30, 2026). Amounts in thousands.

The following tables set forth the reconciliations of each of our NGFMs (other than Net Debt, which is reconciled above) to their most directly comparable financial measures presented in accordance with GAAP.

Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related Non-GAAP Organic Revenue Change percentage:

(a) Revenues of our OTC Wellness Business acquisition are excluded for purposes of calculating Non-GAAP organic revenues. These revenue adjustments relate to our North America and International OTC Healthcare segments.

Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and related Non-GAAP Adjusted Gross Margin percentage:

(a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.

Reconciliation of GAAP General and Administrative Expense and related GAAP General and Administrative Expense percentage to Non-GAAP Adjusted General and Administrative expense and related Non-GAAP Adjusted General and Administrative Expense percentage:... (truncated)l and other acquisition-related professional fees.

Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:

(a)

Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.

(b) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.

Reconciliation of GAAP Net Income and GAAP Diluted Earnings Per Share to Non-GAAP Adjusted Net Income and related Non-GAAP Adjusted Diluted Earnings Per Share:

(a) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating. Management believes this depreciation is not reflective of expected ongoing depreciation levels once the facility is fully remediated and operating at normal production levels.

(b)

Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.

(c) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.

(d) The income tax adjustments are determined using applicable rates in the taxing jurisdictions in which the above adjustments relate and includes both current and deferred income tax expense (benefit) based on the specific nature of specific Non-GAAP performance measure.

Note: Amounts may not add due to rounding.

Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow and Non-GAAP Adjusted Free Cash Flow:

Outlook for Fiscal Year 2027

:

Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Free Cash Flow and Projected Non-GAAP Adjusted Free Cash Flow:

Reconciliation of Projected GAAP Diluted EPS to Projected Non-GAAP Adjusted Diluted EPS (a):

(a) The above reconciliation of this forward-looking non-GAAP financial measure only includes adjustments for Q1 2027 and does not include additional adjustments for the remainder of fiscal 2027. These future adjustments are highly uncertain, given the significant variability and difficulty in making accurate projections of the adjustments related to the Breathe Right portfolio and LaCorium Health acquisitions and the costs associated with Pillar5 manufacturing optimization and integration. As a result, the Company is unable to quantify those future adjustments, which are likely significant, without unreasonable efforts.

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.